TWhat does the Michael J. Fox Foundation do? It funds Parkinson's disease research with a focus on speed and scale, to move science toward a cure and better treatments. How does its work operate? It provides grants and resources to scientists, supports collaborations, and helps advance therapies from discovery to clinical testing, so new drugs and treatments reach patients sooner. How is it different from others? It concentrates only on Parkinson's research, targets aggressive funding and practical translation of findings into therapies, and works across the research community to accelerate progress. What is its goal? To find a cure for Parkinson's disease and to ensure improved therapies are available for people living with it today.
Work here?Claim your company
Industries
Company Size
201-500
Company Stage
N/A
Total Funding
N/A
Headquarters
New York City, New York
Founded
2000
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Word-of-Mouth marketing: how Maplewood, Spectrum, Kendal build buzz. Word-of-mouth awareness is sometimes thought of as the holy grail of senior living marketing. It's also the most difficult to win. Marketing leaders with operators such as Denver, Colorado-based Spectrum Retirement Communities are building brand recognition for the operator's 37 communities through social media marketing, according to William Swearingen, executive vice president of brand management and corporate communications. Conversations on websites like Facebook have become "the new word of mouth," he said. Leaders with Westport, Connecticut-based Maplewood Senior Living and its luxury brand, Inspir, take a more traditional approach to word-of-mouth. The company's marketing message centers on the value a community offers. The company's leaders build relationships with the professionals that families already trust. Creating a good experience from beginning to end can prompt residents to share their experience with family and friends, Maplewood Senior Vice President of Communications Kim Bragoli told SHN Marketing leaders with Newark, Delaware-based Kendal Corp., identify where referrals originate. Between 11% and 15% of the organization's leads or more come from prospects sharing their positive experience with others, Kendal Senior Director of Communications Morgan Lamphere said. 'Grandfluencers' and other buzz. Maplewood's community leaders believe that the best way to generate buzz and excitement is to show people who live nearby what senior living can offer. That's why Maplewood community staff open their doors for events with local organizations or caregiver support groups. Maplewood's Inspir communities, Carnegie Hill in New York City on Manhattan's Upper East Side and Embassy Row in Washington, D.C., offer connections to local cultural institutions, Bragoli said. Maplewood has partnerships with local organizations such as community center 92NY, the Michael J. Fox Foundation, CaringKind, the DC Public Library and the American Federation of the Arts. "Neighborhood partnership is part of the experience," she said. The Spectrum marketing team' posts on social media the various organic moments that occur inside the company's communities, such as hosting the marriage of a resident's daughter or posting videos of residents singing karaoke. The company's marketing team was an early senior living user of TikTok as part of the rise of what one writer at the New York Times dubbed as "grandfluencers". Spectrum's entertainment and activity teams use the company's social media platforms to spotlight local small businesses, such as a local bakery that hosts weekly pop-ups in one of the operator's communities. Showcasing those partnerships is another way to build online buzz. "They can sell their wares inside the community, and then we cross promote by tagging them," Swearingen said. "They then share our post on their pages, and it generates this word of mouth that you simply cannot get any other way." The company's fundraising teams are shifting away from large, national names, such as the Alzheimer's Association, in favor of local charities. Instead of healthcare-related benefits, teams raise money for resident interests, such as the integrity of a library system and paying attention to back-to-school programs in populations that may need support. "There are better ways to be connected to the community and sow yourself as a thread in the local community... It has to be something where there will be a constant evidentiary support that people can see, because what I believe is people react to the organic things, not the not the salesy, predictable market strategy," Swearingen said. Kendal's leaders vary their approach depending on the region and community. While Kendal is a more well-known brand along the East Coast, the organization's marketing teams still are building the brands of two less established West Coast communities. In the instance of Enzo Village in Healdsburg, California, that involves taking a step back and allowing its partner, the San Francisco Zen Center, to take point in facilitating community connections, according to Lamphere. Residents of the organization's Humboldt Commons community in McKinleyville, California, lead education efforts and connect with surrounding businesses to spread the word. "They are people that have been known in the community for the last 40 years," Lamphere said. "Instead of us being there and talking about Kendall, we let them tell that story, and they're the ones that are leading us to the key community partners." Tracking word-of-mouth marketing. Operators have a difficult time tracking word-of-mouth marketing efforts, but that doesn't mean it's impossible. Spectrum's marketing team assigns tracking numbers to social media campaigns. For example, if the marketing team cross-promotes a Chicago-area bakery a community partners with, they create a unique QR code people can use to learn more information, which allows the operator to track its success. Spectrum measures campaigns on engagement, not necessarily revenue or move-ins. "I often refer to it as like a club in college, where if the music isn't pounding when you walk through the doors, you're not going to get on the dance floor," Swearingen said. "In word of mouth advertising, it's very similar to that. You want people to feel something so that they go, 'I want to get on that dance floor and dance.'" Maplewood's leaders are enhancing the company's resident and family ambassadors efforts across its portfolio through a referral program, which rewards between $2,500 and $5,000, depending on the market and community according to Bragoli. The amount is credited on their monthly bill after the referred resident has been within the community for 60 days. Maplewood's leadership team encourages community leadership to build partnerships that reflect the surrounding area, while sharing what works across the portfolio. Meanwhile, Kendal's leaders are building Google review campaigns to not only appear more frequently on web results, but to showcase what a digital word-of-mouth approach looks like for the organization. That campaign takes the form of providing support to each of its affiliates, such as providing postcards with QR codes to direct residents, family members and prospects to the review page, and leading sessions on how to leave a review from a phone. Reminders are given to community members roughly every three months to encourage a review as well. "This is not a strategy that you can apply across the board," Lamphere said. "It's got to be something that is unique for every single market because every market has a different type of influencer that's going to make a bigger difference." Companies featured in this article: Andrew Christman is a reporter for Senior Housing News as part of WTWH Media, an avid reader and writer. He enjoys new book finds from his local library, and playing tabletop games with friends.
Six Jewish billionaires dominate Forbes' wealth rankings with combined fortunes of $1.45 trillion and far-reaching philanthropic legacies. * Jeff Gorman - #TheJewishVoice #JewishVoice * October 14, 2026 * 0 Comments Order Kosher Food By: Jeff Gorman Six of the world's ten wealthiest individuals have Jewish heritage, according to an October 13, 2026 Forbes ranking highlighted by Der Shpiel, underscoring the extraordinary influence of entrepreneurs whose technological innovations have transformed global commerce, communication and information technology. Their combined fortunes, approximately $1.45 trillion, represent an extraordinary concentration of wealth associated with some of the most consequential enterprises of the modern era. According to figures cited by Der Shpiel, Google co-founder Larry Page ranks third worldwide with an estimated fortune of $290.4 billion, followed by Dell Technologies founder Michael Dell in fourth place with $277.3 billion and Google co-founder Sergey Brin in fifth with $267.3 billion. Meta founder Mark Zuckerberg occupies sixth place with $262.5 billion, Oracle co-founder Larry Ellison ranks eighth with $185.4 billion, and former Microsoft chief executive Steve Ballmer stands ninth with $167.8 billion. These fortunes are predominantly tied to corporate ownership and fluctuate with financial markets. Beyond their commercial achievements, several of these billionaires have established substantial philanthropic organizations supporting medical research, education, scientific innovation and community development. The philanthropic dimension of their wealth is particularly significant. Larry Page, whose Google innovations helped transform access to information, established the Carl Victor Page Memorial Foundation with his wife, Lucinda Southworth. According to Inside Philanthropy, the foundation supports climate research, clean energy, scientific advancement, education and health initiatives. Much of its funding passes through charitable accounts that do not publicly identify every ultimate recipient. Sergey Brin has devoted extraordinary resources to medical research, particularly Parkinson's disease. His family foundation has supported the Michael J. Fox Foundation, universities and environmental organizations. Public grant records identify approximately $550 million awarded to the Michael J. Fox Foundation between 2020 and 2024. Michael Dell and his wife, Susan, established their foundation in 1999 to advance children's education, health and economic opportunity. Their philanthropy includes a $6.25 billion commitment to children's investment accounts, intended to benefit approximately 25 million young Americans. Mark Zuckerberg and his wife, Priscilla Chan, created the Chan Zuckerberg Initiative, which concentrates on biomedical research, education and community development. Their scientific ambitions have expanded into artificial intelligence-driven biological research. A newly announced $1.8 billion collaborative initiative aims to accelerate discoveries that could improve disease treatment. Larry Ellison's philanthropic activities include cancer research through the Ellison Medical Institute, alongside earlier support for research into aging, infectious diseases, polio eradication and environmental conservation. Steve Ballmer and his wife, Connie, established Ballmer Group to improve economic mobility. Its investments encompass affordable housing, childhood education, behavioral health and community development. The organization states that its mission is "Economic opportunity for all." As Der Shpiel's wealth rankings illustrate, these six entrepreneurs occupy an exceptional position in the international economy. Their philanthropic commitments additionally demonstrate how fortunes generated through technological innovation can finance scientific discoveries, educational opportunities and initiatives addressing profound social challenges. Their collective influence extends beyond the corporations they built, reaching institutions and communities whose futures may be shaped by the causes they choose to support. Help Support The Jewish Voice and Make a Difference! Independent journalism takes dedication, time and resources. Your support helps The Jewish Voice continue reporting on the people, events and issues that deserve attention, while keeping its coverage accessible to its readers. The Jewish Voice believe access to reliable information is important, and The Jewish Voice is firmly committed to continuing to serve its readers with the kind of stellar journalism that informs, connects and strengthens its community. Your generous contribution helps sustain its journalism and enables The Jewish Voice to continue bringing important stories and perspectives to its readers. Support The Jewish Voice today and help The Jewish Voice continue its work for the years ahead!
Captor Therapeutics secured a $2 million non-dilutive grant from The Michael J. Fox Foundation on September 29, 2026. The money will support its NEK7 project, a brain-penetrant candidate for neurodegenerative diseases, including Parkinson's disease. The Warsaw-listed biotech keeps the intellectual property rights tied to the project. The grant adds funds without a share issue or convertible debt. Captor reported a first-half 2026 net loss of PLN 22.76 million, up from PLN 20.47 million a year earlier. It held PLN 71.5 million in cash and investments at the end of the period, and expects that to fund operations through the third quarter of 2027. The company publishes third-quarter results on November 19, 2026.
Phylo has launched Target Atlas, an AI-powered app that accelerates drug target prioritisation from months to days. Built on the company's Biomni Lab platform, the tool uses AI agents to curate and synthesise evidence across thousands of target–disease assessments whilst leaving final decisions to scientists. The Michael J. Fox Foundation has partnered with Phylo to develop a Parkinson's edition of Target Atlas. The foundation's Targets to Therapies initiative established a transparent prioritisation framework that Target Atlas now makes openly explorable with source-linked analyses. Target choice is critical in drug development, with mechanisms supported by human genetic evidence showing 2.6-fold higher probability of approval success. Target Atlas addresses this by creating continuously updateable, auditable evidence layers across genetics, expression, clinical activity, and safety data. The public edition is free with a Biomni account. Phylo raised $13.5 million in seed funding co-led by Andreessen Horowitz and Menlo Ventures' Anthology Fund.
Phylo launches Target Atlas to speed up target prioritization. * By Phylo, Inc. * Sep 29, 2026 The Michael J. Fox Foundation for Parkinson's Research Targets to Therapies Initiative has partnered with Phylo on a Parkinson's edition of Target Atlas. Hundreds of AI agents curate and synthesize evidence across thousands of target-disease assessments, with the first disease-specific application developed with The Michael J. Fox Foundation Targets to Therapies initiative SOUTH SAN FRANCISCO, Calif., Sept. 29, 2026 /PRNewswire/ - Phylo today launched Target Atlas, an agentic target-prioritization app built on Biomni Lab, the company's Integrated Biology Environment. Target Atlas can cut the evidence-gathering behind target reviews from months of work by teams of scientists to days, creating a shared record that links findings to their sources and can be updated as new research appears. AI agents apply consistent analyses across targets, while scientists decide which evidence matters and how much weight it should carry. Teams can change those weights to see how their own criteria alter the rankings. Free with a Biomni account, the public edition of Target Atlas spans thousands of target-disease assessments, presented through source-linked target profiles and interactive 2x2 plots. ADVERTISING Only about one in ten drug programs that enter clinical development is approved (Hay et al., Nature Biotechnology, 2014). Target choice is one of the earliest and least expensive points at which to change a drug program - and one of the most costly to get wrong - yet the evidence needed to choose well is fragmented across genetics, expression, clinical activity, safety, tractability, biomarkers, competition, and the literature, and changes continuously. Drug mechanisms with human genetic support are associated with an estimated 2.6-fold higher probability of success from Phase 1 to approval (Minikel et al., Nature, 2024). The finding supports a broader premise: stronger, converging evidence at target selection should improve the odds of clinical success, underscoring the value of a current, auditable evidence layer. The Michael J. Fox Foundation's Targets to Therapies (T2T) Initiative established a transparent Parkinson's target-prioritization framework through community nominations, expert panels, curated scorecards, and a published methodology (Vaiana et al., npj Parkinson's Disease, 2025). MJFF's Parkinson's edition of Target Atlas makes that expert framework openly explorable and connects it to source-linked analyses that can be refreshed as new evidence emerges. "The Michael J. Fox Foundation's single, urgent goal remains to find better therapies and a cure for people and families with Parkinson's. Expanding the number of well-characterized, druggable targets is a critical part of the puzzle," said Gaia Skibinski, VP, Head of Translational Therapeutics at The Michael J. Fox Foundation for Parkinson's Research. "As the pace of technology and science evolve, we look forward to exploring how emerging tools in AI, like Phylo's Target Atlas, can help researchers move promising targets toward potential new Parkinson's treatments." "The T2T initiative is exactly the kind of multi-database, multi-expert prioritization that takes a community months to do by hand. Target Atlas shows that agents can assemble and score that evidence in days and keep it current - without replacing the expert judgment that decides which evidence matters. Our collaboration demonstrates what becomes possible when a foundation's expert framework is connected to a continuously updateable evidence layer, and our goal is to bring that model to every major disease," said Kexin Huang, Ph.D., Co-founder and CEO of Phylo. Because target prioritization spans scientists, team leads, and senior R&D leaders, Target Atlas gives teams a shared, source-linked view for comparing evidence and aligning on decisions. Across diseases, versioned computational skills turn evidence from databases, papers, and disease datasets into dashboards and source-linked profiles that record source, date, coverage, and missingness. Researchers can compare targets in interactive 2x2 plots, inspect the evidence behind each result, and use chat to explore the evidence or edit private views. MJFF's Parkinson's edition is one application of the broader Target Atlas, which Phylo plans to expand across all major diseases in the public edition over time. Available by annual license for a governed Biomni deployment, the enterprise edition of Target Atlas enables 20,000-plus targets per selected disease, proprietary data integration, target-pair dashboards, and AI/ML-based scoring. Phylo is seeking foundations, consortia, and patient organizations to sponsor additional disease editions published free to their communities, with each organization's framework represented in scoring. Target Atlas, including the MJFF Parkinson's edition, is available today at https://biomni.phylo.bio. R&D leaders can request an Enterprise demonstration, and foundations and consortia can discuss sponsoring a disease, by reaching out to [email protected]. About Phylo Phylo's mission is to bring the best agentic intelligence to every biomedical scientist. Its enterprise-grade AI platform, Biomni Lab, is the first Integrated Biology Environment - a unified workspace where scientists collaborate with AI agents across literature research, experimental design, biological data analysis, and scientific decision-making. Biomni Lab is now used by leading global biopharma, including Chugai Pharmaceutical and Ono Pharmaceutical. Phylo is based in South San Francisco, and raised a $13.5 million seed round co-led by Andreessen Horowitz (a16z) and Menlo Ventures' Anthology Fund with Anthropic. About The Michael J. Fox Foundation's Targets to Therapies Initiative The Michael J. Fox Foundation for Parkinson's Research (MJFF) launched its Targets to Therapies Initiative in 2024 to expand promising, druggable biological targets in the Parkinson's disease translational pipeline. It combines community-sourced nominations with expert panel-guided prioritization and validation roadmaps, drawing on MJFF datasets and collaborations with Aligning Science Across Parkinson's (ASAP), including the Collaborative Research Network, Parkinson's Progression Markers Initiative, and Global Parkinson's Genetics Program. SOURCE Phylo, Inc.
Find jobs on Simplify and start your career today
Don't see your dream role? Check out thousands of other roles on Simplify.Browse all jobs
Industries
Company Size
201-500
Company Stage
N/A
Total Funding
N/A
Headquarters
New York City, New York
Founded
2000
Find jobs on Simplify and start your career today
Don't see your dream role? Check out thousands of other roles on Simplify.Browse all jobs